Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lansoprazole + naproxen
- Development stage
- Phase 3
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a **combination drug** containing two active pharmaceutical ingredients: **lansoprazole**, a proton pump inhibitor (PPI), and **naproxen**, a nonsteroidal anti-inflammatory drug (NSAID). Lansoprazole decreases gastric acid production by inhibiting the H+/K+ ATPase in gastric parietal cells, protecting the gastric mucosa from NSAID-induced ulcers. Naproxen acts by inhibiting the cyclooxygenase (COX-1 and COX-2) enzymes, reducing the synthesis of prostaglandins and thereby decreasing inflammation, pain, and fever. This fixed-dose combination is primarily indicated to treat **osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis** in patients at risk of NSAID-induced gastric ulcers, combining anti-inflammatory efficacy with gastroprotection[1][2][3][4][6][7].
- Brand names
- Prevacid NapraPAC 375Prevacid NapraPAC 500
- Other names
- lansoprazole and naproxennaproxen-lansoprazoleNapraPAC
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ATP4A (Potassium–transporting ATPase alpha chain 1)VRAC (Volume-regulated anion channel protein LRRC8A)
Beyond the preview
Go deeper on lansoprazole + naproxen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lansoprazole + naproxen.